About this pathway
Background
Zuclopethixol is the cis(Z)-isomer of the racemic drug clopenthixol [Article:11499890]. It is a neuroleptic atypical antipsychotic that acts at the dopamine D1 and D2 receptors [Article:29144549]. It is not approved by the FDA for use in the USA, but is marketed in Canada and Europe for treatment of schizophrenia, [Article:30000827]. It is associated with acquired long QT, extrapyramidal symptoms, metabolic disturbances and neuroleptic malignant syndrome [Article:29144549].
Pharmacokinetics
Zuclopenthixol is converted by CYP2D6 to inactive metabolites zuclopenthixol sulfoxide and n-dealkyl zuclopenthixol [Articles:33000414, 20946203, 7820260, 3439463]. In vitro inhibition experiments also showed involvement of CYP3A4 although it was not clear which metabolites were formed [Article:20946203].
Reactions & interactions (4)
-
Biochemical Reaction
zuclopenthixol → zuclopenthixol sulfoxide
-
Biochemical Reaction
zuclopenthixol → n-dealkyl zuclopenthixol
-
Catalysis
CYP2D6 → Biochemical Reaction
-
Catalysis
CYP2D6 → Biochemical Reaction
Edit history (1)
- 2025-06-11 Create